Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink.

BACKGROUND In 7 large managed care organizations (MCOs), we performed a post-licensure safety assessment of quadrivalent human papillomavirus vaccine (HPV4) among 9-26 year-old female vaccine recipients between August 2006 and October 2009. METHODS Sequential analyses were conducted weekly to detect associations between HPV4 exposure and pre-specified outcomes. The pre-specified outcomes identified by ICD-9 codes using computerized data at the participating MCOs included: Guillan-Barré Syndrome (GBS), stroke, venous thromboembolism (VTE), appendicitis, seizures, syncope, allergic reactions, and anaphylaxis. For rare outcomes, historical background rates were used as the comparison group. For more common outcomes, a concurrent unexposed comparison group was utilized. A standardized review of medical records was conducted for all cases of GBS, VTE, and anaphylaxis. RESULTS A total of 600,558 HPV4 doses were administered during the study period. We found no statistically significant increased risk for the outcomes studied. However, a non-statistically significant relative risk (RR) for VTE ICD-9 codes following HPV4 vaccination of 1.98 was detected among females age 9-17 years. Medical record review of all 8 vaccinated potential VTE cases in this age group revealed that 5 met the standard case definition for VTE. All 5 confirmed cases had known risk factors for VTE (oral contraceptive use, coagulation disorders, smoking, obesity or prolonged hospitalization). CONCLUSIONS In a study of over 600,000 HPV4 vaccine doses administered, no statistically significant increased risk for any of the pre-specified adverse events after vaccination was detected. Further study of a possible association with VTE following HPV4 vaccination is warranted.

[1]  E. Barr,et al.  Quadrivalent-human-papillomavirus-vaccine , 2007, Reactions Weekly.

[2]  Bruce Fireman,et al.  Influenza Vaccination and Mortality: Differentiating Vaccine Effects From Bias , 2009, American journal of epidemiology.

[3]  S. Garland,et al.  Safety of human papillomavirus (HPV) vaccines: a review of the international experience so far. , 2009, Vaccine.

[4]  Larry K. Pickering,et al.  General recommendations on immunization. , 2006, MMWR. Morbidity and mortality weekly report.

[5]  Daron G Ferris,et al.  Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. , 2007, The New England journal of medicine.

[6]  W M O'Fallon,et al.  Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. , 1998, Archives of internal medicine.

[7]  H. Lawson,et al.  Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2007, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[8]  Robert L Davis,et al.  Real-Time Vaccine Safety Surveillance for the Early Detection of Adverse Events , 2007, Medical care.

[9]  K. Ault.  Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials , 2007, The Lancet.

[10]  Robert Ball,et al.  Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. , 2009, JAMA.

[11]  K. K. Lan,et al.  Discrete sequential boundaries for clinical trials , 1983 .

[12]  Larry K. Pickering,et al.  General recommendations on immunization --- recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2006, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[13]  Jan Bonhoeffer,et al.  Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. , 2007, Vaccine.

[14]  J. Sejvar,et al.  Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. , 2011, Vaccine.

[15]  W Katherine Yih,et al.  Measles-Mumps-Rubella-Varicella Combination Vaccine and the Risk of Febrile Seizures , 2010, Pediatrics.

[16]  R. Goldberg,et al.  The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. , 2006, Journal of general internal medicine.

[17]  M. Gold,et al.  Anaphylaxis following quadrivalent human papillomavirus vaccination , 2008, Canadian Medical Association Journal.

[18]  M. Kulldorff,et al.  A Maximized Sequential Probability Ratio Test for Drug and Vaccine Safety Surveillance , 2011 .

[19]  K. Flegal,et al.  Prevalence of high body mass index in US children and adolescents, 2007-2008. , 2010, JAMA.

[20]  W Katherine Yih,et al.  Active Surveillance for Adverse Events: The Experience of the Vaccine Safety Datalink Project , 2011, Pediatrics.

[21]  R. Davis,et al.  Risk of anaphylaxis after vaccination of children and adolescents. , 2003, Pediatrics.

[22]  Oleg O. Bilukha,et al.  Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2000, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[23]  P. Ridker,et al.  Factor V Leiden Mutation and the Risks for Thromboembolic Disease: A Clinical Perspective , 1997, Annals of Internal Medicine.

[24]  M. Moss.  RISK OF ANAPHYLAXIS AFTER VACCINATION OF CHILDREN AND ADOLESCENTS , 2004, Pediatrics.

[25]  C. Dekker,et al.  An Algorithm for Treatment of Patients With Hypersensitivity Reactions After Vaccines , 2008, Pediatrics.

[26]  Virginia Health-System.  Cigarette use among high school students--United States, 1991-2005. , 2006, MMWR. Morbidity and mortality weekly report.

[27]  G. Martinez,et al.  Teenagers in the United States: sexual activity, contraceptive use, and childbearing, national survey of family growth 2006-2008. , 2010, Vital and health statistics. Series 23, Data from the National Survey of Family Growth.